Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;15(5):619-636.
doi: 10.1007/s12015-019-09901-7.

Solid Tumors Challenges and New Insights of CAR T Cell Engineering

Affiliations
Review

Solid Tumors Challenges and New Insights of CAR T Cell Engineering

Safa Tahmasebi et al. Stem Cell Rev Rep. 2019 Oct.

Abstract

Adoptive cell therapy using CAR T cells has emerged as a novel treatment strategy with promising results against B cell malignancies; however, CAR T cells have not shown much success against solid malignancies. There are several obstacles which diminish the efficacy of CAR T cells, but the immunosuppressive tumor microenvironment (TME) of the tumor stands out as the most important factor. TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. A precise understanding of the TME could pave the way to engineer novel modifications of CAR T cells which can overcome the immunosuppressive TME. In this review, we will describe different sections of the TME and introduce novel approaches to improve the CAR T cells potential against solid tumors based on recent clinical and preclinical data. Also, we will provide new suggestions on how to modify CARs to augment of CAR T cells efficacy. Since there are also some challenges beyond the TME that are important for CAR function, we will also discuss and provide data about the improvement of CAR T cells trafficking and delivery to the tumor site and how to solve the problem of tumor antigen heterogeneity.

Keywords: Adoptive cell therapy; CAR T cell; Challenges; Chimeric antigen receptor; Immunotherapy; Solid tumor.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Xia, A.-L., Wang, X.-C., Lu, Y.-J., Lu, X.-J., & Sun, B. (2017). Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: Challenges and opportunities. Oncotarget., 8(52), 90521. - DOI - PubMed - PMC
    1. Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., et al. (2016). A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget., 7(19), 27764. - PubMed - PMC
    1. Elahi, R., Khosh, E., Tahmasebi, S., & Esmaeilzadeh, A. (2018). Immune cell hacking: Challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.01717 .
    1. Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S., et al. (2016). Phase I trial of anti-PSMA designer CAR-T cells in prostate Cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. The Prostate., 76(14), 1257–1270. - DOI - PubMed
    1. Romero, D. (2018). Haematological cancer: Favourable outcomes with CAR T cells. Nature Reviews. Clinical Oncology, 15(2), 65. - DOI - PubMed

Substances

LinkOut - more resources